

Reinhold Kreutz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4702359/publications.pdf>

Version: 2024-02-01

276
papers

21,405
citations

46918

47
h-index

10708

138
g-index

290
all docs

290
docs citations

290
times ranked

25809
citing authors

#	ARTICLE	IF	CITATIONS
1	Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 10-25.	0.4	30
2	2022 World Hypertension League, Resolve To Save Lives and International Society of Hypertension dietary sodium (salt) global call to action. <i>Journal of Human Hypertension</i> , 2023, 37, 428-437.	1.0	22
3	Pain-coping types among older community-dwelling care receivers with chronic pain. <i>Aging and Mental Health</i> , 2022, 26, 1417-1425.	1.5	2
4	Effect of a common UMOD variant on kidney function, blood pressure, cognitive and physical function in a community-based cohort of older adults. <i>Journal of Human Hypertension</i> , 2022, 36, 983-988.	1.0	1
5	Sex Differences in Characteristics Associated with Potentially Inappropriate Medication Use and Associations with Functional Capacity in Older Participants of the Berlin Aging Study II. <i>Gerontology</i> , 2022, 68, 664-672.	1.4	4
6	Blood Pressure and Arterial Stiffness in Association With Aircraft Noise Exposure: Long-Term Observation and Potential Effect of COVID-19 Lockdown. <i>Hypertension</i> , 2022, 79, 325-334.	1.3	19
7	Improving the Management of Hypertension by Tackling Awareness, Adherence, and Clinical Inertia: A Symposium Report. <i>American Journal of Cardiovascular Drugs</i> , 2022, 22, 251-261.	1.0	10
8	Nonadherence in Hypertension: How to Develop and Implement Chemical Adherence Testing. <i>Hypertension</i> , 2022, 79, 12-23.	1.3	51
9	Reply. <i>Journal of Hypertension</i> , 2022, 40, 624-626.	0.3	0
10	Methodological Aspects of Meta-Analyses Assessing the Effect of Blood Pressure "Lowering Treatment on Clinical Outcomes. <i>Hypertension</i> , 2022, 79, 491-504.	1.3	11
11	Cpxm2 as a novel candidate for cardiac hypertrophy and failure in hypertension. <i>Hypertension Research</i> , 2022, 45, 292-307.	1.5	12
12	Is Therapeutic Drug Monitoring Relevant for Antidepressant Drug Therapy? Implications From a Systematic Review and Meta-Analysis With Focus on Moderating Factors. <i>Frontiers in Psychiatry</i> , 2022, 13, 826138.	1.3	8
13	MiRNA-29b and miRNA-497 Modulate the Expression of Carboxypeptidase X Member 2, a Candidate Gene Associated with Left Ventricular Hypertrophy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2263.	1.8	2
14	Do recent meta-analyses truly prove that treatment with blood pressure-lowering drugs is beneficial at any blood pressure value, no matter how low? A critical review. <i>Journal of Hypertension</i> , 2022, 40, 839-846.	0.3	11
15	Hypertension management during the COVID-19 pandemic: what can we learn for the future?. <i>Blood Pressure</i> , 2022, 31, 47-49.	0.7	3
16	Covid-19 associated reduction in hypertension-related diagnostic and therapeutic procedures in Excellence Centers of the European Society of Hypertension. <i>Blood Pressure</i> , 2022, 31, 71-79.	0.7	11
17	Individualized Beta-Blocker Treatment for High Blood Pressure Dictated by Medical Comorbidities: Indications Beyond the 2018 European Society of Cardiology/European Society of Hypertension Guidelines. <i>Hypertension</i> , 2022, 79, 1153-1166.	1.3	20
18	Prescribing blood pressure lowering drugs irrespective of blood pressure?. <i>Journal of Hypertension</i> , 2022, 40, 1050-1051.	0.3	0

#	ARTICLE	IF	CITATIONS
19	Hypertension in older patients: a STEP forward?. Blood Pressure, 2022, 31, 118-120.	0.7	2
20	Mild chronic hypertension in pregnancy: to treat or wait?. Blood Pressure, 2022, 31, 121-124.	0.7	1
21	Thirty years with LIFE—a randomized clinical trial with more than 200 published articles on clinical aspects of left ventricular hypertrophy. Blood Pressure, 2022, 31, 125-128.	0.7	0
22	Effects of Ramipril on Biomarkers of Endothelial Dysfunction and Inflammation in Hypertensive Children on Maintenance Hemodialysis: the SEARCH Randomized Placebo-Controlled Trial. Hypertension, 2022, 79, 1856-1865.	1.3	2
23	Sodium–glucose co-transporter-2 inhibitors for patients with diabetic and nondiabetic chronic kidney disease: a new era has already begun. Journal of Hypertension, 2021, 39, 1090-1097.	0.3	22
24	Prediction of the dose range for adverse neurological effects of amiodarone in patients from an in vitro toxicity test by in vitro–in vivo extrapolation. Archives of Toxicology, 2021, 95, 1433-1442.	1.9	6
25	Anticoagulant treatment for venous thromboembolism: A pooled analysis and additional results of the XALIA and XALIA+LEA noninterventional studies. Research and Practice in Thrombosis and Haemostasis, 2021, 5, 426-438.	1.0	10
26	Starting Antihypertensive Drug Treatment With Combination Therapy. Hypertension, 2021, 77, 800-805.	1.3	9
27	2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement. Journal of Hypertension, 2021, 39, 1293-1302.	0.3	349
28	Hypertension, a Moving Target in COVID-19. Circulation Research, 2021, 128, 1062-1079.	2.0	61
29	Do β -Blockers Cause Depression?. Hypertension, 2021, 77, 1539-1548.	1.3	22
30	MO431LIPIDOMIC ANALYSIS IN A NON-DIABETIC RAT MODEL WITH HYPERFILTRATION AND ALBUMINURIA REVEALS DYNAMIC CHANGES IN THE PROSTAGLANDIN E2 PATHWAY DURING ONSET OF ALBUMINURIA AS A POTENTIAL CAUSATIVE MECHANISM. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	0
31	Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension. Journal of Hypertension, 2021, 39, 1522-1545.	0.3	47
32	High Prevalence of Multimorbidity and Polypharmacy in Elderly Patients With Chronic Pain Receiving Home Care are Associated With Multiple Medication-Related Problems. Frontiers in Pharmacology, 2021, 12, 686990.	1.6	30
33	European Society of Hypertension position paper on renal denervation 2021. Journal of Hypertension, 2021, 39, 1733-1741.	0.3	88
34	Why we do not need a single independent international hypertension clinical practice guideline. Journal of Hypertension, 2021, 39, 2125-2127.	0.3	1
35	Hypertension healthcare professional beliefs and behaviour regarding patient medication adherence: a survey conducted among European Society of Hypertension Centres of Excellence. Blood Pressure, 2021, 30, 282-290.	0.7	13
36	Medical therapies for prevention of cardiovascular and renal events in patients with atrial fibrillation and diabetes mellitus. Europace, 2021, 23, 1873-1891.	0.7	10

#	ARTICLE	IF	CITATIONS
37	Missing Verification of Source Data in Hypertension Research: The HYGIA PROJECT in Perspective. <i>Hypertension</i> , 2021, 78, 555-558.	1.3	28
38	Neuropsychological Functioning in Users of Serotonergic Psychedelics – A Systematic Review and Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2021, 12, 739966.	1.6	4
39	Lifestyle, psychological, socioeconomic and environmental factors and their impact on hypertension during the coronavirus disease 2019 pandemic. <i>Journal of Hypertension</i> , 2021, 39, 1077-1089.	0.3	44
40	Attended vs. unattended blood pressure – learnings beyond SPRINT. <i>Blood Pressure</i> , 2021, 30, 1-3.	0.7	2
41	Rationale and design of XARENO: XA inhibition in RENal patients with non-valvular atrial fibrillation. <i>Observational registry. Kardiologia Polska</i> , 2021, 79, 1265-1267.	0.3	4
42	Blood Pressure Control. , 2021, , 317-322.		1
43	Antihypertensive Drugs. , 2021, , 165-174.		2
44	High-Throughput Sequencing to Investigate Associations Between HLA Genes and Metamizole-Induced Agranulocytosis. <i>Frontiers in Genetics</i> , 2020, 11, 951.	1.1	4
45	TMEM63C, a Potential Novel Target for Albuminuria Development, Is Regulated by MicroRNA-564 and Transforming Growth Factor beta in Human Renal Cells. <i>Kidney and Blood Pressure Research</i> , 2020, 45, 850-862.	0.9	1
46	Hypertension Research Quo Vadis?. <i>Hypertension</i> , 2020, 76, 1423-1424.	1.3	1
47	Tmem63c is a potential pro-survival factor in angiotensin II-treated human podocytes. <i>Life Sciences</i> , 2020, 258, 118175.	2.0	6
48	A practical approach to switch from a multiple pill therapeutic strategy to a polypill-based strategy for cardiovascular prevention in patients with hypertension. <i>Journal of Hypertension</i> , 2020, 38, 1890-1898.	0.3	8
49	Genome-Wide Association Study of Metamizole-Induced Agranulocytosis in European Populations. <i>Genes</i> , 2020, 11, 1275.	1.0	6
50	Impact of single-pill combination therapy on adherence, blood pressure control, and clinical outcomes: a rapid evidence assessment of recent literature. <i>Journal of Hypertension</i> , 2020, 38, 1016-1028.	0.3	36
51	Update of the position paper on arterial hypertension and erectile dysfunction. <i>Journal of Hypertension</i> , 2020, 38, 1220-1234.	0.3	25
52	Finerenone Reduces Intrinsic Arterial Stiffness in Munich Wistar Frã¶mter Rats, a Genetic Model of Chronic Kidney Disease. <i>American Journal of Nephrology</i> , 2020, 51, 294-303.	1.4	29
53	Circadian variations in blood pressure and their implications for the administration of antihypertensive drugs: is dosing in the evening better than in the morning?. <i>Journal of Hypertension</i> , 2020, 38, 1396-1406.	0.3	23
54	Deficits in pain medication in older adults with chronic pain receiving home care: A cross-sectional study in Germany. <i>PLoS ONE</i> , 2020, 15, e0229229.	1.1	14

#	ARTICLE	IF	CITATIONS
55	Pain-Associated Clusters Among Nursing Home Residents and Older Adults Receiving Home Care in Germany. <i>Journal of Pain and Symptom Management</i> , 2020, 60, 48-59.	0.6	0
56	COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. <i>Cardiovascular Research</i> , 2020, 116, 1666-1687.	1.8	1,074
57	Nutraceuticals and blood pressure control: a European Society of Hypertension position document. <i>Journal of Hypertension</i> , 2020, 38, 799-812.	0.3	43
58	Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19. <i>Cardiovascular Research</i> , 2020, 116, 1688-1699.	1.8	282
59	Concerted EP2 and EP4 Receptor Signaling Stimulates Autocrine Prostaglandin E2 Activation in Human Podocytes. <i>Cells</i> , 2020, 9, 1256.	1.8	6
60	Concomitant diabetes with atrial fibrillation and anticoagulation management considerations. <i>European Heart Journal Supplements</i> , 2020, 22, O78-O86.	0.0	15
61	Blood Pressure Control. , 2020, , 1-6.		0
62	Rivaroxaban™s Impact on Renal Decline in Patients With Nonvalvular Atrial Fibrillation: A US MarketScan Claims Database Analysis. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961986853.	0.7	37
63	Fixed-dose combination antihypertensive medications. <i>Lancet, The</i> , 2019, 394, 637-638.	6.3	44
64	Patient Management Strategies and Long-Term Outcomes in Isolated Distal Deep-Vein Thrombosis versus Proximal Deep-Vein Thrombosis: Findings from XALIA. <i>TH Open</i> , 2019, 03, e85-e93.	0.7	20
65	The Impact of Measurement Methods on Office Blood Pressure and Management of Hypertension in General Practice. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2019, 26, 483-491.	1.0	3
66	Patterns of medication use and the burden of polypharmacy in patients with chronic kidney disease: the German Chronic Kidney Disease study. <i>CKJ: Clinical Kidney Journal</i> , 2019, 12, 663-672.	1.4	82
67	Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Severe Kidney Disease or Undergoing Hemodialysis. <i>American Journal of Medicine</i> , 2019, 132, 1078-1083.	0.6	93
68	Glomerular C4d deposition can precede the development of focal segmental glomerulosclerosis. <i>Kidney International</i> , 2019, 96, 738-749.	2.6	14
69	Exposure to vitamin k antagonists and kidney function decline in patients with atrial fibrillation and chronic kidney disease. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 207-216.	1.0	20
70	XALIA-LEA: An observational study of venous thromboembolism treatment with rivaroxaban and standard anticoagulation in the Asia-Pacific, Eastern Europe, the Middle East, Africa and Latin America. <i>Thrombosis Research</i> , 2019, 176, 125-132.	0.8	17
71	Control of blood pressure and risk of mortality in a cohort of older adults: the Berlin Initiative Study. <i>European Heart Journal</i> , 2019, 40, 2021-2028.	1.0	54
72	Longitudinal kidney function trajectories predict major bleeding, hospitalization and death in patients with atrial fibrillation and chronic kidney disease. <i>International Journal of Cardiology</i> , 2019, 282, 47-52.	0.8	5

#	ARTICLE	IF	CITATIONS
73	Pharmacokinetics of Daclatasvir, Sofosbuvir, and GS-331007 in a Prospective Cohort of Hepatitis C Virus-Positive Kidney Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 53-58.	1.0	3
74	Reviewing the effects of thiazide and thiazide-like diuretics as photosensitizing drugs on the risk of skin cancer. <i>Journal of Hypertension</i> , 2019, 37, 1950-1958.	0.3	46
75	Importance of in vitro conditions for modeling the in vivo dose in humans by in vitro-in vivo extrapolation (IVIVE). <i>Archives of Toxicology</i> , 2019, 93, 615-621.	1.9	10
76	Increased dynamin expression precedes proteinuria in glomerular disease. <i>Journal of Pathology</i> , 2019, 247, 177-185.	2.1	11
77	Healthcare resource use in XALIA: A subgroup analysis of a non-interventional study of rivaroxaban versus standard anticoagulation for deep vein thrombosis. <i>European Journal of Internal Medicine</i> , 2019, 61, 29-33.	1.0	3
78	Pain, Fear of Falling, and Functional Performance Among Nursing Home Residents: A Longitudinal Study. <i>Western Journal of Nursing Research</i> , 2019, 41, 191-216.	0.6	8
79	Analysis of the genomic architecture of a complex trait locus in hypertensive rat models links Tmem63c to kidney damage. <i>ELife</i> , 2019, 8, .	2.8	25
80	Treatment Thresholds and Targets in Hypertension. <i>Hypertension</i> , 2018, 71, 966-968.	1.3	11
81	The CHA2DS2-VASc score strongly correlates with glomerular filtration rate and predicts renal function decline over time in elderly patients with atrial fibrillation and chronic kidney disease. <i>International Journal of Cardiology</i> , 2018, 253, 71-77.	0.8	24
82	Improving long-term adherence to statin therapy: a qualitative study of GPs' experiences in primary care. <i>British Journal of General Practice</i> , 2018, 68, e401-e407.	0.7	15
83	Sulfasalazine-Induced Agranulocytosis Is Associated With the Human Leukocyte Antigen Locus. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 843-853.	2.3	18
84	Patient-Reported Treatment Experience with Oral Rivaroxaban: Results from the Noninterventional XALIA Study of Deep-Vein Thrombosis. <i>TH Open</i> , 2018, 02, e139-e146.	0.7	5
85	2018 Practice Guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. <i>Journal of Hypertension</i> , 2018, 36, 2284-2309.	0.3	689
86	ESH Annual Meeting 2018. <i>European Heart Journal</i> , 2018, 39, 3836-3839.	1.0	0
87	2018 Practice guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. <i>Blood Pressure</i> , 2018, 27, 314-340.	0.7	254
88	Atrial fibrillation and medication treatment among centenarians: Are all very old patients treated the same?. <i>Geriatrics and Gerontology International</i> , 2018, 18, 1634-1640.	0.7	4
89	2018 ESC/ESH Guidelines for the management of arterial hypertension. <i>Journal of Hypertension</i> , 2018, 36, 1953-2041.	0.3	2,129
90	Influence of Renal Function on the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Non-Vitamin K Antagonist Oral Anticoagulants. <i>Mayo Clinic Proceedings</i> , 2018, 93, 1503-1519.	1.4	11

#	ARTICLE	IF	CITATIONS
91	FO029HYPERTENSION CONTROL AND MORTALITY IN A COHORT OF OLDER ADULTS. Nephrology Dialysis Transplantation, 2018, 33, i30-i31.	0.4	0
92	Implementing the proclamation of stroke and potentially preventable dementias. Journal of Clinical Hypertension, 2018, 20, 1354-1359.	1.0	7
93	Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress. Frontiers in Pharmacology, 2018, 9, 1131.	1.6	61
94	Implementing the Proclamation of Stroke and Potentially Preventable Dementias. International Journal of Stroke, 2018, 13, 780-786.	2.9	11
95	Moderation of alcohol consumption as a recommendation in European hypertension management guidelines: a survey on awareness, screening and implementation among European physicians. BMJ Open, 2018, 8, e022026.	0.8	8
96	Lower Prescription Rates in Centenarians with Heart Failure and Heart Failure and Kidney Disease Combined: Findings from a Longitudinal Cohort Study of Very Old Patients. Drugs and Aging, 2018, 35, 907-916.	1.3	4
97	Targeted resequencing of a locus for heparin-induced thrombocytopenia on chromosome 5 identified in a genome-wide association study. Journal of Molecular Medicine, 2018, 96, 765-775.	1.7	10
98	2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal, 2018, 39, 3021-3104.	1.0	6,826
99	Predictive value of venous thromboembolism (<sc>VTE</sc>)â€<sc>BLEED</sc> to predict major bleeding and other adverse events in a practiceâ€based cohort of patients with <sc>VTE</sc>: results of the <sc>XALIA</sc> study. British Journal of Haematology, 2018, 183, 457-465.	1.2	32
100	Single-Pill Triple Fixed Dose Combination Therapy with Single Component Drug Monitoring in Treatment-Resistant Hypertension: A Pilot Study. Current Vascular Pharmacology, 2018, 16, 197-203.	0.8	7
101	Drug-induced kidney injury: A large case series from the Berlin Case-Control Surveillance Study. Clinical Nephrology, 2018, 89, 18-26.	0.4	14
102	Pain management intervention targeting nursing staff and general practitioners: Pain intensity, consequences and clinical relevance for nursing home residents. Geriatrics and Gerontology International, 2017, 17, 1534-1543.	0.7	14
103	Analysis of patients with deep vein thrombosis switched from standard therapy to rivaroxaban in the non-interventional XALIA study. Thrombosis Research, 2017, 155, 23-27.	0.8	9
104	Donor Genotype and Intragraft Expression of CYP3A5 Reflect the Response to Steroid Treatment During Acute Renal Allograft Rejection. Transplantation, 2017, 101, 2017-2025.	0.5	8
105	Immobilization and high platelet count are associated with thromboembolic complications in heparin-induced thrombocytopenia. Pharmacoepidemiology and Drug Safety, 2017, 26, 1149-1155.	0.9	3
106	Uromodulin associates with cardiorenal function in patients with hypertension and cardiovascular disease. Journal of Hypertension, 2017, 35, 2053-2058.	0.3	12
107	The impact of Î±-Lipoic acid on cell viability and expression of nephrin and ZNF580 in normal human podocytes. European Journal of Pharmacology, 2017, 810, 1-8.	1.7	7
108	Subgroup Analysis of Patients with Cancer in XALIA: A Noninterventional Study of Rivaroxaban versus Standard Anticoagulation for VTE. TH Open, 2017, 01, e33-e42.	0.7	18

#	ARTICLE	IF	CITATIONS
109	Small molecules as therapy for uveitis: a selected perspective of new and developing agents. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1311-1323.	0.9	16
110	Personalised Single-Pill Combination Therapy in Hypertensive Patients: An Update of a Practical Treatment Platform. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2017, 24, 463-472.	1.0	14
111	Statin intolerance "a question of definition. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 55-63.	1.0	14
112	Towards new recommendations to reduce the burden of alcohol-induced hypertension in the European Union. <i>BMC Medicine</i> , 2017, 15, 173.	2.3	24
113	The effects of timing of prophylaxis, type of anesthesia, and use of mechanical methods on outcome in major orthopedic surgery - subgroup analyses from 17,701 patients in the XAMOS study. <i>Vascular Health and Risk Management</i> , 2016, 12, 209.	1.0	9
114	Herb-Induced Liver Injury in the Berlin Case-Control Surveillance Study. <i>International Journal of Molecular Sciences</i> , 2016, 17, 114.	1.8	33
115	Regulation of podoplanin expression by microRNA-29b associates with its antiapoptotic effect in angiotensin II-induced injury of human podocytes. <i>Journal of Hypertension</i> , 2016, 34, 323-331.	0.3	26
116	Validation of a Modified German Version of the Brief Pain Inventory for Use in Nursing Home Residents with Chronic Pain. <i>Journal of Pain</i> , 2016, 17, 248-256.	0.7	13
117	Genetic variants associated with antithyroid drug-induced agranulocytosis: a genome-wide association study in a European population. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 507-516.	5.5	78
118	Genetic low nephron number hypertension is associated with altered expression of key components of the renin-angiotensin system during nephrogenesis. <i>Journal of Perinatal Medicine</i> , 2016, 44, 705-9.	0.6	2
119	Rivaroxaban compared with standard thromboprophylaxis after major orthopaedic surgery: co-medication interactions. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 724-734.	1.1	17
120	Physician Contacts and Their Influence on the Appropriateness of Pain Medication in Nursing Home Residents: A Cross-Sectional Study. <i>Journal of the American Medical Directors Association</i> , 2016, 17, 834-838.	1.2	4
121	Role of matrix metalloproteinase-9 in chronic kidney disease: a new biomarker of resistant albuminuria. <i>Clinical Science</i> , 2016, 130, 525-538.	1.8	48
122	Evaluation einer Fortbildung für Pflegenden zum Schmerzmanagement in Pflegeheimen. <i>Heilberufe</i> , 2016, 7, 9-18.	0.7	3
123	Real life studies and good clinical practice "Authors' reply. <i>Lancet Haematology</i> , 2016, 3, e160-e161.	2.2	1
124	Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study. <i>Lancet Haematology</i> , 2016, 3, e12-e21.	2.2	215
125	Metformin modulates apoptosis and cell signaling of human podocytes under high glucose conditions. <i>Journal of Nephrology</i> , 2016, 29, 765-773.	0.9	44
126	Aptamer BC007 for neutralization of pathogenic autoantibodies directed against G-protein coupled receptors: A vision of future treatment of patients with cardiomyopathies and positivity for those autoantibodies. <i>Atherosclerosis</i> , 2016, 244, 44-47.	0.4	33

#	ARTICLE	IF	CITATIONS
127	Rivaroxaban for Thromboprophylaxis After Fracture-Related Orthopedic Surgery in Routine Clinical Practice. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2016, 22, 138-146.	0.7	18
128	Subgroup Analysis of Patients with Cancer in Xalia - a Non-Interventional Study of Rivaroxaban in Routine Treatment of Deep Vein Thrombosis. <i>Blood</i> , 2016, 128, 1438-1438.	0.6	2
129	Falls Self-Efficacy in German Nursing Home Residents: Assessment of Validity and Determination of a Cutoff Point. <i>Research in Gerontological Nursing</i> , 2016, 9, 134-144.	0.2	4
130	Novel Drugs in the Treatment of Hypertension. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2016, , 157-178.	0.1	0
131	Development of progressive albuminuria in male Munich Wistar Fr�mter rats is androgen dependent. <i>Physiological Genomics</i> , 2015, 47, 281-289.	1.0	3
132	Novel candidate genes for impaired nephron development in a rat model with inherited nephron deficit and albuminuria. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2015, 42, 1051-1058.	0.9	2
133	A Single Nucleotide Polymorphism near the CYP17A1 Gene Is Associated with Left Ventricular Mass in Hypertensive Patients under Pharmacotherapy. <i>International Journal of Molecular Sciences</i> , 2015, 16, 17456-17468.	1.8	9
134	Nonpharmacologic Pain Management Interventions in German Nursing Homes: A Cluster Randomized Trial. <i>Pain Management Nursing</i> , 2015, 16, 464-474.	0.4	23
135	Drug-induced liver injury: results from the hospital-based Berlin Case-Control Surveillance Study. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 988-999.	1.1	62
136	Cardiorenal protection in experimental hypertension with renal failure: comparison between vasopeptidase inhibition and angiotensin receptor blockade. <i>Clinical and Experimental Hypertension</i> , 2015, 37, 26-32.	0.5	4
137	Estimating kidney function and use of oral antidiabetic drugs in elderly. <i>Fundamental and Clinical Pharmacology</i> , 2015, 29, 321-328.	1.0	17
138	Metamizole-induced agranulocytosis revisited: results from the prospective Berlin Case-Control Surveillance Study. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 219-227.	0.8	63
139	Xalia, a Non-Interventional Study Comparing Rivaroxaban with Standard Anticoagulation for Initial and Long-Term Therapy in Deep Vein Thrombosis. <i>Blood</i> , 2015, 126, 894-894.	0.6	2
140	Fetal-Adult Cardiac Transcriptome Analysis in Rats with Contrasting Left Ventricular Mass Reveals New Candidates for Cardiac Hypertrophy. <i>PLoS ONE</i> , 2015, 10, e0116807.	1.1	4
141	A genome-wide association study identifies 6p21 as novel risk locus for dilated cardiomyopathy. <i>European Heart Journal</i> , 2014, 35, 1069-1077.	1.0	137
142	Genetic Variants on Rat Chromosome 8 Exhibit Profound Effects on Hypertension Severity and Survival During Nitric Oxide Inhibition in Spontaneously Hypertensive Rats. <i>American Journal of Hypertension</i> , 2014, 27, 294-298.	1.0	2
143	Impact of socio-economic factors on the long-term effectiveness of antihypertensive treatment with an angiotensin II receptor blocker: an observational study. <i>Current Medical Research and Opinion</i> , 2014, 30, 1947-1955.	0.9	0
144	Efficacy and Tolerability of Triple-Combination Therapy With Olmesartan, Amlodipine, and Hydrochlorothiazide: A Subgroup Analysis of Patients Stratified by Hypertension Severity, Age, Sex, and Obesity. <i>Journal of Clinical Hypertension</i> , 2014, 16, 729-740.	1.0	7

#	ARTICLE	IF	CITATIONS
145	Flupirtine-induced liver injury—Seven cases from the Berlin Case—control Surveillance Study and review of the German spontaneous adverse drug reaction reporting database. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 453-459.	0.8	27
146	A clinical and pharmacologic assessment of once-daily versus twice-daily dosing for rivaroxaban. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 38, 137-149.	1.0	25
147	ARB-Based Single-Pill Platform to Guide a Practical Therapeutic Approach to Hypertensive Patients. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2014, 21, 137-47.	1.0	25
148	XALIA: rationale and design of a non-interventional study of rivaroxaban compared with standard therapy for initial and long-term anticoagulation in deep vein thrombosis. <i>Thrombosis Journal</i> , 2014, 12, 16.	0.9	27
149	Drug-induced agranulocytosis in the Berlin case—control surveillance study. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 339-345.	0.8	46
150	Hotline update of clinical trials and registries presented at the American College of Cardiology Congress 2014. <i>Clinical Research in Cardiology</i> , 2014, 103, 591-597.	1.5	2
151	Neutralization of pathogenic beta1-receptor autoantibodies by aptamers in vivo: the first successful proof of principle in spontaneously hypertensive rats. <i>Molecular and Cellular Biochemistry</i> , 2014, 393, 177-180.	1.4	21
152	Insufficient anticoagulation with dabigatran in a patient with short bowel syndrome. <i>Thrombosis and Haemostasis</i> , 2014, 112, 419-420.	1.8	18
153	A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment. <i>Thrombosis and Haemostasis</i> , 2014, 111, 94-102.	1.8	74
154	Pharmacokinetics and Pharmacodynamics of Rivaroxaban — An Oral, Direct Factor Xa Inhibitor. <i>Current Clinical Pharmacology</i> , 2014, 9, 75-83.	0.2	44
155	Ophthalmic Drugs as Part of Polypharmacy in Nursing Home Residents with Glaucoma. <i>Drugs and Aging</i> , 2013, 30, 31-38.	1.3	20
156	Influence of CYP2D6-genotype on tamoxifen efficacy in advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 553-560.	1.1	23
157	Genetics of melatonin receptor type 2 is associated with left ventricular function in hypertensive patients treated according to guidelines. <i>European Journal of Internal Medicine</i> , 2013, 24, 650-655.	1.0	14
158	Ramipril-Induced Liver Injury: Case Report and Review of the Literature. <i>American Journal of Hypertension</i> , 2013, 26, 1070-1075.	1.0	17
159	Mapping and confirmation of a major left ventricular mass QTL on rat chromosome 1 by contrasting SHRSP and F344 rats. <i>Physiological Genomics</i> , 2013, 45, 827-833.	1.0	3
160	Dissecting the genetic predisposition to albuminuria and endothelial dysfunction in a genetic rat model. <i>Journal of Hypertension</i> , 2013, 31, 2203-2212.	0.3	20
161	Genetic low nephron number hypertension is associated with altered expression of osteopontin and CD44 during nephrogenesis*. <i>Journal of Perinatal Medicine</i> , 2013, 41, 295-299.	0.6	2
162	Are physicians underestimating the challenges of hypertension management? Results from the Supporting Hypertension Awareness and Research Europe-wide (SHARE) survey. <i>European Journal of Preventive Cardiology</i> , 2013, 20, 786-792.	0.8	14

#	ARTICLE	IF	CITATIONS
163	Perceived enactment of autonomy of nursing home residents: A German cross-sectional study. <i>Australian Journal of Cancer Nursing</i> , 2013, 15, 186-193.	0.8	10
164	Dialysis-Associated Hypertension Treated with Telmisartan – DiaTel: A Pilot, Placebo-Controlled, Cross-Over, Randomized Trial. <i>PLoS ONE</i> , 2013, 8, e79322.	1.1	2
165	Induction of albuminuria and kidney damage in SHR by transfer of chromosome 8 from Munich Wistar Frmter rats. <i>Physiological Genomics</i> , 2012, 44, 110-116.	1.0	7
166	CYP3A5 Genotype-Phenotype Analysis in the Human Kidney Reveals a Strong Site-Specific Expression of CYP3A5 in the Proximal Tubule in Carriers of the CYP3A5*1 Allele. <i>Drug Metabolism and Disposition</i> , 2012, 40, 639-641.	1.7	24
167	MWF rats with spontaneous albuminuria inherit a reduced efficiency of nephron induction during early nephrogenesis in comparison to SHR rats. <i>Journal of Hypertension</i> , 2012, 30, 2031-2038.	0.3	10
168	Physical Activity in Nursing Homes – Barriers and Facilitators: A Cross-Sectional Study. <i>Journal of Aging and Physical Activity</i> , 2012, 20, 421-441.	0.5	45
169	The First Aptamer-Apheresis Column Specifically for Clearing Blood of β_2 -Receptor Autoantibodies. <i>Circulation Journal</i> , 2012, 76, 2449-2455.	0.7	28
170	Management consensus guidance for the use of rivaroxaban – an oral, direct factor Xa inhibitor. <i>Thrombosis and Haemostasis</i> , 2012, 108, 876-886.	1.8	155
171	Genetic variants implicated in telomere length associated with left ventricular function in patients with hypertension and cardiac organ damage. <i>Journal of Molecular Medicine</i> , 2012, 90, 1059-1067.	1.7	12
172	Mapping genetic determinants of kidney damage in rat models. <i>Hypertension Research</i> , 2012, 35, 675-694.	1.5	33
173	Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery. <i>Vascular Health and Risk Management</i> , 2012, 8, 363.	1.0	17
174	Anticontractile Effect of Perivascular Adipose Tissue and Leptin are Reduced in Hypertension. <i>Frontiers in Pharmacology</i> , 2012, 3, 103.	1.6	78
175	Pharmacodynamic and pharmacokinetic basics of rivaroxaban. <i>Fundamental and Clinical Pharmacology</i> , 2012, 26, 27-32.	1.0	97
176	Olmesartan/amlodipine: a review of its use in the management of hypertension. <i>Vascular Health and Risk Management</i> , 2011, 7, 183.	1.0	27
177	Role of CYP2C9 genetic variants for salt sensitivity and the regulation of the renin-angiotensin-aldosterone system in normotensive men. <i>Journal of Hypertension</i> , 2011, 29, 56-61.	0.3	6
178	Physician attitudes to blood pressure control. <i>Journal of Hypertension</i> , 2011, 29, 1633-1640.	0.3	37
179	Differential impact of the CYP3A5*1 and CYP3A5*3 alleles on pre-dose concentrations of two tacrolimus formulations. <i>Pharmacogenetics and Genomics</i> , 2011, 21, 179-184.	0.7	43
180	Prescribing of inappropriate medication in nursing home residents in Germany according to a French consensus list: a cross-sectional cohort study. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 12-19.	0.9	20

#	ARTICLE	IF	CITATIONS
181	Efficacy and safety of a fixed-dose combination of lercanidipine and enalapril in daily practice. A comparison of office, self-measured and ambulatory blood pressure. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2771-2779.	0.9	18
182	Elimination of Severe Albuminuria in Aging Hypertensive Rats by Exchange of 2 Chromosomes in Double-Consomic Rats. <i>Hypertension</i> , 2011, 58, 219-224.	1.3	20
183	Impact of Nephron Number Dosing on Cardiorenal Damage and Effects of ACE Inhibition. <i>American Journal of Hypertension</i> , 2011, 24, 474-481.	1.0	9
184	Microangiopathy and visual deficits characterize the retinopathy of a spontaneously hypertensive rat model with type 2 diabetes and metabolic syndrome. <i>Hypertension Research</i> , 2011, 34, 103-112.	1.5	7
185	Safety and efficacy of olmesartan: an observational pooled-analysis of 156,682 hypertensive patients. <i>Expert Opinion on Drug Safety</i> , 2011, 10, 185-196.	1.0	7
186	Decreased cardiac SERCA2 expression, SR Ca uptake, and contractile function in hypothyroidism are attenuated in SERCA2 overexpressing transgenic rats. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2011, 300, H943-H950.	1.5	8
187	Role of the angiotensin II type 2 receptor gene (+1675G/A) polymorphism on left ventricular hypertrophy and geometry in treated hypertensive patients. <i>Journal of Hypertension</i> , 2010, 28, 1221-1229.	0.3	7
188	Genetic locus on MWF rat chromosome 6 affects kidney damage in response to α -NAME treatment in spontaneously hypertensive rats. <i>Physiological Genomics</i> , 2010, 42, 126-133.	1.0	11
189	Tissue Expression of TRPC3 and TRPC6 in Hypertensive Munich Wistar Frömter Rats Showing Proteinuria. <i>American Journal of Nephrology</i> , 2010, 31, 36-44.	1.4	10
190	Renal ACE2 expression and activity is unaltered during established hypertension in adult SHRSP and TGR(mREN2)27. <i>Hypertension Research</i> , 2010, 33, 123-128.	1.5	17
191	Role of the H1 haplotype of microtubule-associated protein tau (MAPT) gene in Greek patients with Parkinson's disease. <i>BMC Neurology</i> , 2009, 9, 26.	0.8	15
192	Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects. <i>Fundamental and Clinical Pharmacology</i> , 2009, 23, 767-774.	1.0	15
193	Short-term treatment with a beta-blocker with vasodilative capacities improves intrarenal endothelial function in experimental renal failure. <i>Life Sciences</i> , 2009, 85, 431-437.	2.0	14
194	Effects of basic fibroblast growth factor on endothelial cells under conditions of simulated microgravity. <i>Journal of Cellular Biochemistry</i> , 2008, 104, 1324-1341.	1.2	57
195	Selective Loss of Podoplanin Protein Expression Accompanies Proteinuria and Precedes Alterations in Podocyte Morphology in a Spontaneous Proteinuric Rat Model. <i>American Journal of Pathology</i> , 2008, 173, 315-326.	1.9	53
196	Quality of life in hypertension management using olmesartan in primary care. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 1641-1653.	0.9	12
197	Genetic analysis of salt-sensitive hypertension in Dahl rats reveals a link between cardiac fibrosis and high cholesterol. <i>Cardiovascular Research</i> , 2008, 81, 618-626.	1.8	17
198	Lack of Association Between the <i>MEF2A</i> Gene and Myocardial Infarction. <i>Circulation</i> , 2008, 117, 185-191.	1.6	44

#	ARTICLE	IF	CITATIONS
199	A Twofold Genetic Increase of ACE Expression Has No Effect on the Development of Spontaneous Hypertension. <i>American Journal of Hypertension</i> , 2008, 21, 200-205.	1.0	4
200	Genetic predisposition for glomerulonephritis-induced glomerulosclerosis in rats is linked to chromosome 1. <i>Physiological Genomics</i> , 2008, 35, 173-181.	1.0	4
201	Protective effect of female gender on the development of albuminuria in a polygenetic rat model is enhanced further by replacement of a major autosomal QTL. <i>Clinical Science</i> , 2008, 114, 305-311.	1.8	14
202	Nephron deficit is not required for progressive proteinuria development in the Munich Wistar Frmter rat. <i>Physiological Genomics</i> , 2008, 35, 30-35.	1.0	29
203	Development of Overt Proteinuria in the Munich Wistar Frmter Rat Is Suppressed by Replacement of Chromosome 6 in a Consomic Rat Strain. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 113-121.	3.0	32
204	Profiling of the renal kinome: a novel tool to identify protein kinases involved in angiotensin II-dependent hypertensive renal damage. <i>American Journal of Physiology - Renal Physiology</i> , 2007, 293, F428-F437.	1.3	18
205	Rat chromosome 19 transfer from SHR ameliorates hypertension, salt-sensitivity, cardiovascular and renal organ damage in salt-sensitive Dahl rats. <i>Journal of Hypertension</i> , 2007, 25, 95-102.	0.3	11
206	Induction of C1q expression in glomerular endothelium in a rat model with arterial hypertension and albuminuria. <i>Journal of Hypertension</i> , 2007, 25, 2308-2316.	0.3	11
207	High sodium intake modulates left ventricular mass in patients with G expression of +1675 G/A angiotensin II receptor type 2 gene. <i>Journal of Hypertension</i> , 2007, 25, 1627-1632.	0.3	14
208	The G-231A Polymorphism in the Endothelin-A Receptor Gene Is Associated With Lower Aortic Pressure in Patients With Dilated Cardiomyopathy. <i>American Journal of Hypertension</i> , 2007, 20, 32-37.	1.0	10
209	Left-Ventricular Structure and Function Are Influenced by Angiotensinogen Gene Polymorphism (~20) Tj ETQq1 1 0,784314,rgBT /Over	1.0	10
210	Monocytes From Spontaneously Hypertensive Rats Show Increased Store-Operated and Second Messenger-Operated Calcium Influx Mediated by Transient Receptor Potential Canonical Type 3 Channels. <i>American Journal of Hypertension</i> , 2007, 20, 1111-1118.	1.0	29
211	Expression of vascular endothelial growth factor and receptor tyrosine kinases in cardiac ischemia/reperfusion injury. <i>Cardiovascular Pathology</i> , 2007, 16, 291-299.	0.7	40
212	Modeled gravitational unloading induced downregulation of endothelin-1 in human endothelial cells. <i>Journal of Cellular Biochemistry</i> , 2007, 101, 1439-1455.	1.2	88
213	Pharmacokinetics of Olmesartan Medoxomil plus Hydrochlorothiazide Combination in Healthy Subjects. <i>Clinical Drug Investigation</i> , 2006, 26, 29-34.	1.1	18
214	Pharmacokinetics and Safety of Olmesartan Medoxomil in Combination with Glibenclamide in Healthy Volunteers. <i>Clinical and Experimental Hypertension</i> , 2006, 28, 631-643.	0.5	7
215	No association of the CYP3A5*1 allele with blood pressure and left ventricular mass and geometry: the KORA/MONICA Augsburg echocardiographic substudy. <i>Clinical Science</i> , 2006, 111, 365-372.	1.8	12
216	Expression and Response to Angiotensin-Converting Enzyme Inhibition of Matrix Metalloproteinases 2 and 9 in Renal Glomerular Damage in Young Transgenic Rats with Renin-Dependent Hypertension. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 316, 8-16.	1.3	44

#	ARTICLE	IF	CITATIONS
217	Genetic low nephron number hypertension is associated with dysregulation of the hepatic and renal insulin-like growth factor system during nephrogenesis. <i>Journal of Hypertension</i> , 2006, 24, 1857-1864.	0.3	15
218	Simulated weightlessness changes the cytoskeleton and extracellular matrix proteins in papillary thyroid carcinoma cells. <i>Cell and Tissue Research</i> , 2006, 324, 267-277.	1.5	87
219	Physiology of Local Renin-Angiotensin Systems. <i>Physiological Reviews</i> , 2006, 86, 747-803.	13.1	1,433
220	Low-dose lithium combined with captopril prevents stroke and improves survival in salt-loaded, stroke-prone spontaneously hypertensive rats. <i>Journal of Hypertension</i> , 2005, 23, 2277-2285.	0.3	15
221	The role of the cytochrome P450 3A5 enzyme for blood pressure regulation in the general Caucasian population. <i>Pharmacogenetics and Genomics</i> , 2005, 15, 831-837.	0.7	29
222	Increase of fibronectin and osteopontin in porcine hearts following ischemia and reperfusion. <i>Journal of Molecular Medicine</i> , 2005, 83, 626-637.	1.7	45
223	An Expectation-Maximization "Likelihood-Ratio Test for Handling Missing Data. <i>Genetics</i> , 2005, 169, 1021-1031.	1.2	7
224	Increased Transient Receptor Potential Channel TRPC3 Expression in Spontaneously Hypertensive Rats. <i>American Journal of Hypertension</i> , 2005, 18, 1503-1507.	1.0	68
225	Genetic linkage of albuminuria and renal injury in Dahl salt-sensitive rats on a high-salt diet: comparison with spontaneously hypertensive rats. <i>Physiological Genomics</i> , 2004, 18, 218-225.	1.0	36
226	Pharmacogenetics of antihypertensive drug response. <i>Current Hypertension Reports</i> , 2004, 6, 15-20.	1.5	13
227	The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patients. <i>Pharmacogenetics and Genomics</i> , 2004, 14, 665-671.	5.7	57
228	Genetic kininogen deficiency contributes to aortic aneurysm formation but not to atherosclerosis. <i>Physiological Genomics</i> , 2004, 19, 41-49.	1.0	35
229	Nephroprotective effects of the endothelin ETA receptor antagonist darusentan in salt-sensitive genetic hypertension. <i>European Journal of Pharmacology</i> , 2003, 468, 209-216.	1.7	15
230	Cardiac fibrosis occurs early and involves endothelin and AT-1 receptors in hypertension due to endogenous angiotensin II. <i>Journal of the American College of Cardiology</i> , 2003, 41, 666-673.	1.2	94
231	A Major Gene Locus Links Early Onset Albuminuria with Renal Interstitial Fibrosis in the MWF Rat with Polygenetic Albuminuria. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 3081-3089.	3.0	58
232	Role of the Endothelin-1 Gene Locus for Renal Impairment in the General Nondiabetic Population. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 2596-2602.	3.0	25
233	Interaction between blood pressure quantitative trait loci in rats in which trait variation at chromosome 1 is conditional upon a specific allele at chromosome 10. <i>Human Molecular Genetics</i> , 2003, 12, 435-439.	1.4	35
234	Genetic Loci Contribute to the Progression of Vascular and Cardiac Hypertrophy in Salt-Sensitive Spontaneous Hypertension. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 1211-1217.	1.1	27

#	ARTICLE	IF	CITATIONS
235	Renal damage is not improved by blockade of endothelin receptors in primary renin-dependent hypertension. <i>Journal of Hypertension</i> , 2003, 21, 2389-2397.	0.3	19
236	Congenic strains confirm the presence of salt-sensitivity QTLs on chromosome 1 in the Sabra rat model of hypertension. <i>Physiological Genomics</i> , 2003, 12, 85-95.	1.0	38
237	Early onset albuminuria in Dahl rats is a polygenetic trait that is independent from salt loading. <i>Physiological Genomics</i> , 2003, 14, 209-216.	1.0	33
238	Genetic Dissection of Increased Urinary Albumin Excretion in the Munich Wistar Fr�mter Rat. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 2706-2714.	3.0	62
239	Endothelin-A Receptor Blockade Prevents Left Ventricular Hypertrophy and Dysfunction in Salt-Sensitive Experimental Hypertension. <i>Circulation</i> , 2002, 106, 2305-2308.	1.6	36
240	Early onset of chondroitin sulfate and osteopontin expression in angiotensin ii-dependent left ventricular hypertrophy1. <i>American Journal of Hypertension</i> , 2002, 15, 644-652.	1.0	52
241	Matrix analysis for the dissection of interactions of G-Protein �23 subunit C825T genotype, allograft function, and posttransplant hypertension in kidney transplantation. <i>American Journal of Kidney Diseases</i> , 2002, 40, 1319-1324.	2.1	8
242	Impaired coronary endothelial function in a rat model of spontaneous albuminuria. <i>Kidney International</i> , 2002, 62, 181-191.	2.6	37
243	Isolation of Renal Glomeruli Specific Cell Material Using an Experimental NIR-Laser Microdissection Setup. <i>Medical Laser Application: International Journal for Laser Treatment and Research</i> , 2002, 17, 21-24.	0.4	0
244	Congenic rat strains are important tools for the genetic dissection of essential hypertension. <i>Seminars in Nephrology</i> , 2002, 22, 135-147.	0.6	18
245	Effects of angiotensin II subtype 1 receptor blockade on cardiac fibrosis and sarcoplasmic reticulum Ca ²⁺ handling in hypertensive transgenic rats overexpressing the Ren2 gene. <i>Journal of Hypertension</i> , 2001, 19, 1465-1472.	0.3	15
246	Upregulation of the vascular NAD(P)H-oxidase isoforms Nox1 and Nox4 by the renin-angiotensin system in vitro and in vivo. <i>Free Radical Biology and Medicine</i> , 2001, 31, 1456-1464.	1.3	244
247	Renal Endothelin ET _A /ET _B Receptor Imbalance Differentiates Salt-Sensitive From Salt-Resistant Spontaneous Hypertension. <i>Hypertension</i> , 2001, 37, 275-280.	1.3	46
248	Impaired Function of Endothelial Pressure-Activated Cation Channel in Salt-Sensitive Genetic Hypertension. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 1624-1629.	3.0	5
249	Effect of high NaCl diet on spontaneous hypertension in a genetic rat model with reduced nephron number. <i>Journal of Hypertension</i> , 2000, 18, 777-782.	0.3	61
250	Acute blood pressure effects of YC-1-induced activation of soluble guanylyl cyclase in normotensive and hypertensive rats. <i>British Journal of Pharmacology</i> , 2000, 130, 205-208.	2.7	45
251	Extracellular Signal-regulated Kinase Plays an Essential Role in Hypertrophic Agonists, Endothelin-1 and Phenylephrine-induced Cardiomyocyte Hypertrophy. <i>Journal of Biological Chemistry</i> , 2000, 275, 37895-37901.	1.6	166
252	Cardiac Endothelin System Impairs Left Ventricular Function in Renin-Dependent Hypertension via Decreased Sarcoplasmic Reticulum Ca ²⁺ Uptake. <i>Circulation</i> , 2000, 102, 1582-1588.	1.6	42

#	ARTICLE	IF	CITATIONS
253	The Trp64Arg polymorphism of the β -adrenergic receptor gene is associated with hypertension in men with type 2 diabetes mellitus. <i>American Journal of Hypertension</i> , 2000, 13, 1027-1031.	1.0	39
254	Role of Chromosome X in the Sabra Rat Model of Salt-Sensitive Hypertension. <i>Hypertension</i> , 1999, 33, 261-265.	1.3	38
255	Congenetic Substitution Mapping Excludes <i>Sa</i> as a Candidate Gene Locus for a Blood Pressure Quantitative Trait Locus on Rat Chromosome 1. <i>Hypertension</i> , 1999, 34, 643-648.	1.3	62
256	Co-expression of renin-angiotensin system genes in human adipose tissue. <i>Journal of Hypertension</i> , 1999, 17, 555-560.	0.3	201
257	Salt Susceptibility Maps to Chromosomes 1 and 17 With Sex Specificity in the Sabra Rat Model of Hypertension. <i>Hypertension</i> , 1998, 31, 119-124.	1.3	64
258	Differential Development of Early Hypertension in Heterozygous Transgenic TGR(mREN2)27 Rats. <i>Clinical and Experimental Hypertension</i> , 1998, 20, 273-282.	0.5	7
259	Molekular definierte Modelle in der Herz-Kreislauf-Forschung. , 1998, , 401-412.		0
260	Hpa II polymorphism of the atrial natriuretic peptide gene and the blood pressure response to salt intake in normotensive men. <i>Journal of Hypertension</i> , 1997, 15, 715-718.	0.3	29
261	A Gene-Based Genetic Linkage and Comparative Map of the Rat X Chromosome. <i>Genomics</i> , 1997, 40, 253-261.	1.3	47
262	Evidence for Primary Genetic Determination of Heart Rate Regulation. <i>Circulation</i> , 1997, 96, 1078-1081.	1.6	27
263	Role of the β ₁ , β ₂ , and β ₃ -Subunits of Epithelial Sodium Channel in a Model of Polygenic Hypertension. <i>Hypertension</i> , 1997, 29, 131-136.	1.3	42
264	Association Between the Angiotensinogen 235T-Variant and Essential Hypertension in Whites. <i>Hypertension</i> , 1997, 30, 1331-1337.	1.3	155
265	Effect of Losartan on Right Ventricular Hypertrophy and Cardiac Angiotensin I-Converting Enzyme Activity in Pulmonary Hypertensive Rats. <i>Clinical and Experimental Hypertension</i> , 1996, 18, 101-111.	0.5	13
266	Development, genotype and phenotype of a new colony of the Sabra hypertension prone (SBH/y) and resistant (SBN/y) rat model of salt sensitivity and resistance. <i>Journal of Hypertension</i> , 1996, 14, 1175-1182.	0.3	47
267	Chromosomal mapping of quantitative trait loci contributing to stroke in a rat model of complex human disease. <i>Nature Genetics</i> , 1996, 13, 429-434.	9.4	237
268	The Y Chromosome. <i>Hypertension</i> , 1996, 28, 895-897.	1.3	23
269	Angiotensin II receptor blockade in TGR(mREN2)27: effects of renin-angiotensin-system gene expression and cardiovascular functions. <i>Journal of Hypertension</i> , 1995, 13, 891-899.	0.3	91
270	A Prospective Evaluation of an Angiotensin-Converting Enzyme Gene Polymorphism and the Risk of Ischemic Heart Disease. <i>New England Journal of Medicine</i> , 1995, 332, 706-712.	13.9	864

#	ARTICLE	IF	CITATIONS
271	Angiotensin-Converting Enzyme I/D Polymorphism and Arterial Wall Thickness in a General Population. <i>Circulation</i> , 1995, 91, 2721-2724.	1.6	117
272	Altered Angiotensinogen Amino Acid Sequence and Plasma Angiotensin II Levels in Genetically Hypertensive Rats. <i>Hypertension</i> , 1995, 26, 279-284.	1.3	11
273	Dissociation of Renin and Aldosterone During Low-Dose Epinephrine Infusion. <i>American Journal of Hypertension</i> , 1994, 7, 913-918.	1.0	4
274	Membrane microviscosity does not correlate with blood pressure: a cosegregation study. <i>Journal of Hypertension</i> , 1993, 11, 25-30.	0.3	14
275	Molecular Genetics of Hypertension. <i>Clinical and Experimental Hypertension</i> , 1992, 14, 15-34.	0.3	6
276	Cell biology in hypertension. <i>Current Opinion in Cardiology</i> , 1991, 6, 680-685.	0.8	1